ライフサイエンスコーパス: renal mass

1 in the upper pole of the kidney, mimicking a renal mass.

2 ist to review the approach to the incidental renal mass.

3 damental role in the care of patients with a renal mass.

4 atory hyperfiltration following reduction in renal mass.

5 ider percutaneous biopsy when encountering a renal mass.

6 ociated with chronic proteinuria and loss of renal mass.

7 any renal diseases and adaptation to loss of renal mass.

8 velop renal injury after severe reduction of renal mass.

9 One child also demonstrated an echogenic renal mass.

10 veins, smaller right kidney, or cystic right renal mass.

11 cally in association with reduced functional renal mass.

12 rimental renal disease in a model of reduced renal mass.

13 ive antagonist A-127722 in rats with reduced renal mass.

14 ed were all markedly modulated by changes in renal mass.

15 t on hypertension produced by a reduction in renal mass.

16 ry are down-regulated by providing increased renal mass.

17 icktly adjoined to the left kidney mimicking renal mass.

18 elop methods for estimating functional donor renal mass.

19 adaptive changes that follow a reduction in renal mass.

20 al complications and inadequate islet and/or renal mass.

21 estoration of euvolemia, and preservation of renal mass.

22 before surgical resection (median 4 d) of a renal mass.

23 duction of renal mass), or sham reduction of renal mass.

24 T/CT (DPSMA) for the evaluation of localized renal mass.

25 rated DPSMA uptake and kinetics in localized renal masses.

26 ecisions on how to treat patients with small renal masses.

27 managing newly diagnosed patients with small renal masses.

28 plant patients who underwent nephrectomy for renal masses.

29 to stratify the risk of malignancy in cystic renal masses.

30 ological diseases such as urinary stones and renal masses.

31 e ablative method for the treatment of small renal masses.

32 elpful in characterizing and differentiating renal masses.

33 tomography (CT), for the treatment of solid renal masses.

34 a basis for differential diagnosis of other renal masses.

35 distinguishing between benign and malignant renal masses.

36 has become more common for the treatment of renal masses.

37 e of percutaneous biopsy in the diagnosis of renal masses.

38 dings were similar in the majority of cystic renal masses.

39 emerged as the treatment of choice for small renal masses.

40 cterization, and post-operative follow-up of renal masses.

41 distinguishing between benign and malignant renal masses.

42 n with CT to characterize 31 "indeterminate" renal masses.

43 7 patients (18 male, 9 female) with 36 solid renal masses.

44 cal decision making during surgery for large renal masses.

45 , and detecting macroscopic fat within solid renal masses.

46 -sestamibi SPECT/CT for characterizing solid renal masses.

47 or carefully selected individuals with small renal masses.

48 in two independent cohorts of patients with renal masses.

49 PECT/CT was performed on 42 patients with 62 renal masses.

50 umber of incidentally detected indeterminate renal masses.

51 an age, 57.3 years; 67 male, 58 female) with renal masses.

52 predict the malignancy and aggressiveness of renal masses.

53 fication tool among patients with suspicious renal masses.

54 imaging for many incompletely characterized renal masses.

55 and in the differential diagnosis of imaged renal masses.

56 f many incompletely characterized incidental renal masses.

57 001) with integrin alphavbeta3 expression in renal masses.

58 as a potential tool for evaluating localized renal masses.

59 of MRI for lipid-poor AMLs in patients with renal masses.

60 iagnosis and staging of benign and malignant renal masses.

61 method for characterization of indeterminate renal masses.

62 c or solid renal masses and those who had no renal masses.

63 ally invasive partial nephrectomies for such renal masses.

64 best management approaches for patients with renal masses.

65 sses, nonsimple or solid renal masses, or no renal masses.

66 imally invasive surgical extirpation of cT1b renal masses.

67 rminate renal lesions, 1 patient had a solid renal mass, 1 patient had sclerotic bone metastases (alb

68 trong predictor of benignity in an exophytic renal mass 2 cm or greater in diameter with high specifi

69 older patient with comorbidities and a small renal mass ( 4 cm).

70 aged 18 years or older with an indeterminate renal mass 7 cm or smaller (cT1) suspicious for clear-ce

71 MR images from 108 pathologically proved renal masses (88 clear cell RCCs and 20 minimal fat AMLs

72 Among solid renal masses, a more aggressive overall approach is take

73 he adaptive responses of remnant nephrons to renal mass ablation, these data suggest that ANP of rena

74 renal growth, suggesting that an increase in renal mass above a normal level requires the activation

75 We review the natural history of small renal masses according to the current literature, and hi

76 model designed to predict the malignancy of renal masses achieves area under the curve (AUC) of 0.87

77 radiologists the lead role in the work-up of renal masses, an area where urologists once held forth.

78 ion, reverses fibroinflammation and restores renal mass and function.

79 I (AngII) type I receptor blocker, preserved renal mass and gross morphology of the obstructed kidney

80 n all Agt genotypes, UUO reduced ipsilateral renal mass and increased that of the opposite kidney.

81 ats subjected to a 75% surgical reduction of renal mass and normotensive sham-operated control rats.

82 ing population, the absence or presence of a renal mass and RCC were verified by abdominal CT and by

83 The signal intensity (SI) of each renal mass and spleen on opposed-phase and in-phase GRE

84 composition algorithm in patients undergoing renal mass and urinary stone evaluation.

85 Renal function (GFR) was reduced by loss of renal mass and was reduced further in proteinuric rats w

86 Of 1159 patients with simple cyst-appearing renal masses and a minimum of 5 years of follow-up, six

87 iologists to improve the diagnosis of benign renal masses and differentiate cancers that are biologic

88 Improving the diagnosis of benign renal masses and distinguishing aggressive cancers from

89 variate logistic regression analysis for all renal masses and for small masses.

90 on-of-interest measurements were obtained in renal masses and in the gallbladder or low-density renal

91 of the imaging features of specific kinds of renal masses and more accurate imaging-guided biopsy are

92 Of 446 patients with nonsimple or solid renal masses and sufficient follow-up, 50 (11%) develope

93 gic features of neoplastic and nonneoplastic renal masses and their radiologic analogues, described a

94 with those who had nonsimple cystic or solid renal masses and those who had no renal masses.

95 onflict between those treating patients with renal masses and those with an interest in renal donatio

96 ting Bosniak category IV lesion and/or solid renal mass, and multiplicity of Bosniak III lesions were

97 based on imaging characteristics for cystic renal masses, and detecting macroscopic fat within solid

98 nign prostatic hyperplasia, prostate cancer, renal masses, and renal calculi have resulted in enhance

99 his approach ideal for posterior and lateral renal masses, and technically feasible with the advances

100 Treatment decisions for an incidental renal mass are mostly made with pathologic uncertainty.

101 cause a considerable fraction of small solid renal masses are benign and do not need treatment, there

102 Radiologically, cystic and solid renal masses are categorized and evaluated separately be

103 As more renal masses are diagnosed in the elderly or comorbid pa

104 However, most renal masses are either too small to characterize comple

105 gests that a significant percentage of small renal masses are indolent and possess a low metastatic r

106 Small renal masses are now a clinical entity that require mana

107 cinoma and the detection of incidental small renal masses are rising.

108 Simple cyst-appearing renal masses are unlikely to be malignant.

109 robability of malignancy in cystic and solid renal masses, are provided for two types of patients, th

110 Differences in renal mass attenuation between VUE and TUE images were w

111 d of malignant and aggressive pathology of a renal mass based on preoperative multi-phase CT images.

112 donors with a diagnosis of incidental small renal mass before implantation and their corresponding r

113 get data of patients who underwent RAPN for renal masses between January 2018 and May 2023 at our In

114 for a large proportion of these tumours, but renal mass biopsies (RMBs) have an increasing role in de

115 ncocytoma based on image-guided percutaneous renal mass biopsy and evaluate patient outcomes followin

116 Further, a recent renewed interest in renal mass biopsy for risk stratification in SRMs has oc

117 ng to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrect

118 Two strategies were compared: renal mass biopsy to triage patients to surgery or imagi

119 Although percutaneous renal mass biopsy with cross-sectional imaging guidance

120 eviews reported experience with percutaneous renal mass biopsy, discusses the technical factors that

121 .001) was a significant predictor of benign renal mass but mass size (P = .66) was not.

122 articipate in the adaptation to reduction in renal mass by changing the steady-state distribution of

123 tive of RCC and were found to have an imaged renal mass by CT.

124 Reduction of renal mass by unilateral nephrectomy results in an immed

125 Stratification of patients with renal masses by (124)I-cG250 PET can identify aggressive

126 ealous use of radical nephrectomy for the T1 renal mass, by whatever surgical approach, must now be c

127 With imaging, most incidental renal masses can be diagnosed promptly and with confiden

128 Most incidental renal masses can be diagnosed with confidence and either

129 resonance imaging (MRI) is commonly used for renal mass characterization and assessment of tumour thr

130 nhanced (VUE) images were unlikely to change renal mass classification as enhancing mass versus nonen

131 Renal mass classification as enhancing mass versus nonen

132 ery is the gold standard treatment for small renal masses confirmed malignant, ablative therapies are

133 Eighty-one cystic renal masses containing calcification in a wall or septu

134 ell RCC (cases) and 162 patients with benign renal masses (controls).

135 Purpose To determine whether renal mass CT performed by using VNC images allows for r

136 cated homogeneous high-attenuating (> 30-HU) renal masses detected at postcontrast CT enables differe

137 nd There is uncertainty in the management of renal masses diagnosed as oncocytomas with image-guided

138 these lesions, and stress the limitations in renal mass diagnosis.

139 therapeutic agent in the context of reduced renal mass did not mitigate the development of fibrosis,

140 g modalities have increased the frequency of renal mass discovery.

141 ve a role in predicting growth rate of solid renal masses during active surveillance.

142 stage migration toward diagnosis of smaller renal masses, energy ablative techniques are being incre

143 b administration and before resection of the renal mass(es).

144 Results: Of 29 enhancing renal masses evaluated in 27 patients, 24 (83%) were mal

145 ith histologically characterized solid small renal masses, excluding lipid-rich angiomyolipomas, unde

146 ced by dietary acid and animals with reduced renal mass exhibit increased urinary ET-1 excretion, the

147 tial nephrectomy for treatment of T1b and T2 renal mass, focusing oncological and renal functional ou

148 in vivo would spare the patient with a solid renal mass from unnecessary biopsies prior to surgery, o

149 contrast-enhanced US with 1018 indeterminate renal masses from 1999 to 2010, identified initially wit

150 rt 2 included 247 patients with small (cT1a) renal masses from an academic biorepository, of whom 184

151 SPECT/CT for clinical work-up of their solid renal masses from September 2018 to October 2021 were re

152 ave on the discovery and characterization of renal masses has been detailed in the pages of Radiology

153 pproach to the image interpretation of solid renal masses has not been broadly implemented.

154 Children born with reduced congenital renal mass have an increased risk of hypertension and ch

155 cades, new modalities for treatment of small renal mass have emerged but despite their evolution and

156 r, hyperfiltration damage related to reduced renal mass, have also been proposed as factors in the ca

157 n widely adopted for the management of small renal masses; however, usage in T1b (greater than 4 cm)

158 should remain the standard of care for small renal masses, if the renal tumor size and complexity are

159 n 11844 (75%), and nonsimple cystic or solid renal masses in 1182 (8%).

160 s were identified in 2669 patients (17%), no renal masses in 11844 (75%), and nonsimple cystic or sol

161 e database yielded 160 biopsy reports of 149 renal masses in 139 patients; 149 masses were categorize

162 A total of 162 exophytic (2 cm or greater) renal masses in 152 patients (103 men, 49 women; mean ag

163 Images of 69 renal masses in 59 patients (38 men, 21 women; mean age,

164 are effective treatment modalities for small renal masses in the infirm patient.

165 s, we find a higher percentage of incidental renal masses in these donors as a result of the inherent

166 Common and uncommon renal masses, in concert with clinical and other imaging

167 tions that may improve imaging assessment of renal masses include standardized assessment of cystic a

168 There were 26 benign small renal masses (including 18 oncocytomas, seven lipid-poor

169 might be considered in the patient in whom a renal mass is detected in the clinical setting of infect

170 Calcification in a cystic renal mass is not as important in diagnosis as is the pr

171 e data show that the quantity of functioning renal mass is not only an important independent determin

172 Furthermore, in general, one in five small renal masses is histologically benign and may not benefi

173 Treatment selection of renal masses is informed largely by size.

174 amibi SPECT/CT for characterization of solid renal masses is limited.

175 The natural history of small renal masses is not completely understood.

176 of percutaneous biopsy for the diagnosis of renal masses is now more commonplace as urologists and r

177 The natural history of small renal masses is still largely unknown; however, initial

178 Management of T1b and T2 renal masses is transforming with adoption of partial ne

179 MR) imaging equipment, the diagnosis of most renal masses is usually straightforward and accurate.

180 ailure, who was subsequently found to have a renal mass, is described.

181 effective and preferable approach to the T1 renal mass, it remains markedly underutilized in the USA

182 s recommending partial nephrectomy for small renal masses, it is essential to understand the benefits

183 For patients with renal masses less than 4 cm in size (48% of patients), p

184 nce for some patients (especially those with renal masses <2 cm).

185 older patient with comorbidities and a small renal mass (<=4 cm).

186 The indolent natural history of small renal masses mandates that we await 10-year data, as wel

187 easibility of RPN in the management of small renal masses, many of them in complex locations.

188 Observation of small renal masses may represent a viable clinical option.

189 ng, such as structural or functional loss of renal mass, may accelerate progression of adult polycyst

190 ell-demarcated, homogeneous high-attenuating renal masses (mean diameter, 2.5 cm; range, 1-4 cm) dete

191 age, 58.1 years) underwent MR imaging of 113 renal masses (mean diameter, 5.4 cm) with pathologic dia

192 deviation]; 31 men, 13 women) with 47 solid renal masses measuring at least 1 cm who underwent two c

193 wo primary approaches have been explored for renal mass molecular imaging.

194 eview as pertaining to simple cyst-appearing renal masses, nonsimple or solid renal masses, or no ren

195 retroperitoneal ganglioneuroma that mimicked renal mass on imaging.

196 among different histopathologic diagnoses in renal masses on the basis of their perfusion level.

197 the patient with either a small asymptomatic renal mass or a small hyperattenuating mass that meets t

198 Patients with a solid renal mass or complex cystic renal mass should be referr

199 formed in patients undergoing evaluation for renal mass or urinary stone.

200 ass), right uninephrectomy (50% reduction of renal mass), or sham reduction of renal mass.

201 t-appearing renal masses, nonsimple or solid renal masses, or no renal masses.

202 asses than that in nonsimple cystic or solid renal masses (P < .0001).

203 s significantly different from that of other renal masses (P < .0002); in 16 (59%) of 27 patients wit

204 %-10% were significantly higher in malignant renal masses (P = .018, P = .002, P = .036, P = .016, P

205 -appearing renal masses versus those without renal masses (P = .54).

206 However, some renal masses, particularly small ones, remain indetermin

207 Among patients with renal masses, pKIM-1 is associated with malignant pathol

208 sist in risk stratification of indeterminate renal masses, potentially contributing to optimal patien

209 ly differentiate malignant from benign small renal masses preoperatively; consequently, 20% of patien

210 the notable growth in the detection of small renal masses presumably corresponding to localized tumor

211 reader assessment was performed in which 195 renal masses prospectively considered Bosniak IIF-IV wer

212 Anatomic imaging of renal masses provides limited information on the histolo

213 e recent guidelines for the management of T1 renal masses put forth by the American Urological Associ

214 When faced with the finding of a small renal mass, radiologists must determine whether it is be

215 were separate from the simple cyst-appearing renal mass, rather than within it.

216 and SEL evaluation was also performed to the renal mass (RCC) of the patient.

217 Here, we investigate whether renal mass reduction affects primary cilia length and fu

218 Renal mass reduction and growth factor treatment was ass

219 els of hypertension and in mice subjected to renal mass reduction as a model of CKD.

220 tubules to redifferentiate in rats with 75% renal mass reduction associated with more severe capilla

221 Previously, it was shown that 5/6 renal mass reduction by surgical excision (RK-NX) result

222 Oxidative stress from renal mass reduction contributes to the glomerular and t

223 ermore, initially normotensive rats with 75% renal mass reduction developed hypertension and proteinu

224 In summary, severe (>50%) renal mass reduction disproportionately compromised tubu

225 the functional derangements associated with renal mass reduction in the rat.

226 Renal dysfunction after congenital renal mass reduction is associated with impaired regulat

227 ced hypertension; and early mortality in the renal mass reduction model.

228 ssed the impact of prior graded normotensive renal mass reduction on ischemia-reperfusion-induced AKI

229 after ischemia-reperfusion in rats with 75% renal mass reduction relative to other groups.

230 y failed repair of AKI in kidneys with prior renal mass reduction triggers hemodynamically mediated p

231 perfusion occurs when there is already a 50% renal mass reduction, but not when two kidneys remain in

232 paired compensatory glomerular adaptation to renal mass reduction, indicating that kidney regeneratio

233 To induce renal mass reduction, mice were subjected to unilateral

234 Proteinuria was unaffected by renal mass reduction.

235 protection from the progression of CRD after renal mass reduction.

236 sponsible for the initiation of GS after 5/6 renal mass reduction.

237 least in part, the renal injury attendant to renal mass reduction.

238 er and intermachine agreement-of solid small renal masses relative to the cortex in the arterial phas

239 Cryoablation of small renal masses represents an alternative method for perfor

240 dney compensation, induced by a reduction of renal mass, results in primary cilia elongation, and thi

241 summarize their approach to the diagnosis of renal masses, review the imaging findings in these lesio

242 h poles of the left kidney (75% reduction of renal mass), right uninephrectomy (50% reduction of rena

243 Rats with reduced renal mass (RRM rats) and sham-operated rats were then m

244 Twenty-six patients with renal masses scheduled for surgical resection received (

245 ts with a solid renal mass or complex cystic renal mass should be referred to urology.

246 Background Solid small renal masses (SRMs) (<=4 cm) represent benign and malign

247 PURPOSE OF REVIEW: Small renal masses (SRMs) are frequently encountered due to th

248 g-based denoising (DLD), in evaluating small renal masses (SRMs) during active surveillance.

249 POSE OF REVIEW: Management options for small renal masses (SRMs) include excision, ablation, and acti

250 benign and malignant solid and cystic small renal masses (SRMs), predicting histologic subtypes, and

251 ard of care for treatment of localized small renal masses (SRMs).

252 e management options for patients with small renal masses (SRMs).

253 s not informed of an incidental finding of a renal mass suggestive of cancer on a magnetic resonance

254 malignant renal tumors compared with benign renal masses, supporting further assessment of DPSMA as

255 enal lesions, presence of a coexistent solid renal mass, surgical pathologic findings, and presence o

256 lower in patients with simple cyst-appearing renal masses than that in nonsimple cystic or solid rena

257 ntirely for those incompletely characterized renal masses that are highly likely to be benign cysts a

258 Today, the majority of solid renal masses that are ultimately proved to be renal cell

259 igh confidence can also be assigned to those renal masses that exhibit the radiologic analogues for h

260 progression to metastases or death for small renal masses that have undergone active surveillance (in

261 l advances in the imaging-based diagnosis of renal masses, the increased detection of incidental rena

262 ients electing radical nephrectomy for small renal masses, the kidney, following excision of the tumo

263 as led to more incidentally discovered small renal masses, the optimal treatment has evolved.

264 In hyperechoic renal masses, the presence of shadowing, a hypoechoic ri

265 In renal masses, this signal intensity loss-which is consis

266 le of radiology in the care of patients with renal masses undergoing active surveillance.

267 -one patients with hematuria or a suspicious renal mass underwent CT urography, during which thinly c

268 two consecutive patients suspected of having renal masses underwent ASL MR imaging before their routi

269 range, 19-95 years; 112 men, 81 women) with renal masses underwent total or partial nephrectomy and

270 y urologic problems, including urolithiasis, renal masses, urinary tract infection, trauma, and obstr

271 dence in patients with simple cyst-appearing renal masses versus those without renal masses (P = .54)

272 rode insertion and/or repositioning into the renal mass was achieved in all cases with direct MR "flu

273 erest measurement of signal intensity of the renal mass was divided by that of reference tissue.

274 with allografts from recipients where total renal mass was reduced (by ligating branches of the graf

275 Traditionally, the treatment of suspicious renal masses was radical nephrectomy.

276 The Bosniak classification system for cystic renal masses was updated in 2019 in part to improve agre

277 Equivalent degrees of reduction in renal mass were confirmed by the similarity of serum cre

278 Eight donors with incidental renal mass were detected (four live and four deceased do

279 Contrast enhancement features of renal masses were evaluated in terms of CT attenuation v

280 rd deviation, 61 years 14; 129 men) with 273 renal masses were evaluated.

281 Simple cyst-appearing renal masses were identified in 2669 patients (17%), no

282 iagnosis of lipid-poor AMLs in patients with renal masses were included.

283 Renal masses were larger (p < 0.001) and at higher compl

284 by antibody PET, and all nine non-clear-cell renal masses were negative for the tracer.

285 fore partial nephrectomy or enucleation; 205 renal masses were removed (92% were <3 cm).

286 Reports that included renal masses were selected, then categorized through man

287 Although very rare, a relatively large renal mass which shows very infiltrative growth pattern

288 tumor enucleation as a safe alternative for renal masses which are locally confined on preoperative

289 Active surveillance of renal masses, which includes serial imaging with the pos

290 se series of patients with a newly diagnosed renal mass who were referred for surgery was examined.

291 ds identified 43 patients with biopsy-proved renal masses who underwent in-phase and opposed-phase MR

292 124)I) -girentuximab PET/CT in patients with renal masses who were scheduled for resection.

293 26 patients with renal masses who were scheduled to undergo surgical rese

294 e diagnosis and management of the incidental renal mass will be suggested.

295 asses, the increased detection of incidental renal masses with cross-sectional imaging poses problems

296 Patients who had renal masses with homogeneous water attenuation, hairlin

297 A clinical study to characterize renal masses with positron emission tomography/computed

298 e for patients who had simple cyst-appearing renal masses with those who had nonsimple cystic or soli

299 e reference standards for treating the small renal mass, with laparoscopic partial nephrectomy increa

300 r cell renal cell carcinoma from other solid renal masses, with a negative predictive value of 88%.